Michael Morabito
Stock Analyst at Chardan Capital
(0.01)
# 4,373
Out of 4,820 analysts
11
Total ratings
9.09%
Success rate
-28.42%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Michael Morabito
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AKRO Akero Therapeutics | Maintains: Buy | $79 → $81 | $42.13 | +92.26% | 2 | Mar 17, 2021 | |
| MDGL Madrigal Pharmaceuticals | Maintains: Buy | $202 → $203 | $332.16 | -38.88% | 2 | Feb 26, 2021 | |
| DRRX DURECT | Maintains: Buy | $70 → $80 | $0.61 | +13,014.75% | 2 | Feb 3, 2021 | |
| ETNB 89bio | Maintains: Buy | $59 → $95 | $7.41 | +1,182.05% | 3 | Sep 15, 2020 | |
| VKTX Viking Therapeutics | Maintains: Buy | $15 → $20 | $25.94 | -22.90% | 2 | Aug 31, 2020 |
Akero Therapeutics
Mar 17, 2021
Maintains: Buy
Price Target: $79 → $81
Current: $42.13
Upside: +92.26%
Madrigal Pharmaceuticals
Feb 26, 2021
Maintains: Buy
Price Target: $202 → $203
Current: $332.16
Upside: -38.88%
DURECT
Feb 3, 2021
Maintains: Buy
Price Target: $70 → $80
Current: $0.61
Upside: +13,014.75%
89bio
Sep 15, 2020
Maintains: Buy
Price Target: $59 → $95
Current: $7.41
Upside: +1,182.05%
Viking Therapeutics
Aug 31, 2020
Maintains: Buy
Price Target: $15 → $20
Current: $25.94
Upside: -22.90%